Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Grant of Options and PDMR Dealing
Cambridge UK, 23 May: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, announces that on 22 May 2024, it granted a total of 540,000 options under the Company's Long Term Incentive Plan ("LTIP Options") and 383,250 options under the Company's All Employee Share Ownership Plan ("AESOP Options"), over new ordinary shares of 1 pence each in the Company ("Ordinary Shares").
The LTIP Options have an exercise price of 1 pence and are granted to certain persons discharging managerial responsibilities ("PDMRs") of the Company. Performance conditions include commercial objectives and Total Shareholder Return during the three-year performance period. The LTIP Options are subject to continued service and the extent to which the performance conditions are satisfied. Vested LTIP Options will normally be exercisable until the tenth anniversary of the grant date, after which time they will lapse. They are subject to a condition that the LTIP Options or the Ordinary Shares acquired on exercise of the LTIP Options (other than those sold to cover tax and National Insurance) are held for a minimum one-year period from vesting.
The AESOP Options vest after 36 months and are exercisable at £1.585 per share, being the closing market price of an Ordinary Share on the day preceding the date of grant. The AESOP Options are subject to continuous employment and are exercisable until the tenth anniversary of the date of grant, after which date the option will lapse. The grant of AESOP Options included 184,000 AESOP Options granted to certain PDMRs.
The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail.
For further information, please contact:
| Arecor Therapeutics plc | |
| Dr Sarah Howell, Chief Executive Officer | Tel: +44 (0) 1223 426060 Email: info@arecor.com
|
| | |
| Susan Lowther, Chief Financial Officer | Tel: +44 (0) 1223 426060 Email: info@arecor.com
|
|
| |
| Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) | Tel: +44 (0) 20 7886 2500
|
|
| |
| | |
| WG Partners LLP (Financial Advisor) | |
| Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang | Tel: +44 (0)203 705 9321 |
|
| |
| ICR Consilium | |
| Chris Gardner, David Daley, Lindsey Neville | Tel: +44 (0) 20 3709 5700 Email: arecor@consilium-comms.com |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat ™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
| Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a) | Name: | David Gerring | ||||||
| 2. | Reason for the notification | |||||||
| a) | Position/status: | SVP Development | ||||||
| b) | Initial notification/Amendment: | Initial notification | ||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a) | Name: | Arecor Therapeutics plc | ||||||
| b) | LEI: | 98450093D12I3A8DDD58 | ||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 1 pence each GB00BMWLM973 | ||||||
| b) | Nature of the transaction: | Grant of options over ordinary shares | ||||||
| c) | Price(s) and volume(s): |
| ||||||
| d) | Aggregated information: · Aggregated volume: · Price: |
106,000 N/A | ||||||
| e) | Date of the transaction: | 22 May 2024 | ||||||
| f) | Place of the transaction: | Outside of a trading venue | ||||||
|
|
| |||||||
|
| Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a) | Name: | Sarah Howell | ||||||
| 2. | Reason for the notification | |||||||
| a) | Position/status: | Chief Executive Officer | ||||||
| b) | Initial notification/Amendment: | Initial notification | ||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a) | Name: | Arecor Therapeutics plc | ||||||
| b) | LEI: | 98450093D12I3A8DDD58 | ||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 1 pence each GB00BMWLM973 | ||||||
| b) | Nature of the transaction: | Grant of options over ordinary shares | ||||||
| c) | Price(s) and volume(s): |
| ||||||
| d) | Aggregated information: · Aggregated volume: · Price: |
226,000 N/A | ||||||
| e) | Date of the transaction: | 22 May 2024 | ||||||
| f) | Place of the transaction: | Outside of a trading venue | ||||||
| | | | ||||||
|
| Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a) | Name: | Manjit Rahelu | ||||||
| 2. | Reason for the notification | |||||||
| a) | Position/status: | Chief Business Officer | ||||||
| b) | Initial notification/Amendment: | Initial notification | ||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a) | Name: | Arecor Therapeutics plc | ||||||
| b) | LEI: | 98450093D12I3A8DDD58 | ||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 1 pence each GB00BMWLM973 | ||||||
| b) | Nature of the transaction: | Grant of options over ordinary shares | ||||||
| c) | Price(s) and volume(s): |
| ||||||
| d) | Aggregated information: · Aggregated volume: · Price: |
73,000 N/A | ||||||
| e) | Date of the transaction: | 22 May 2024 | ||||||
| f) | Place of the transaction: | Outside of a trading venue | ||||||
|
|
| |||||||
|
| Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a) | Name: | Jan Jezek | ||||||
| 2. | Reason for the notification | |||||||
| a) | Position/status: | Chief Scientific Officer | ||||||
| b) | Initial notification/Amendment: | Initial notification | ||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a) | Name: | Arecor Therapeutics plc | ||||||
| b) | LEI: | 98450093D12I3A8DDD58 | ||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 1 pence each GB00BMWLM973 | ||||||
| b) | Nature of the transaction: | Grant of options over ordinary shares | ||||||
| c) | Price(s) and volume(s): |
| ||||||
| d) | Aggregated information: · Aggregated volume: · Price: |
106,000 N/A | ||||||
| e) | Date of the transaction: | 22 May 2024 | ||||||
| f) | Place of the transaction: | Outside of a trading venue | ||||||
| | | | ||||||
|
| Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a) | Name: | Helen Parris | ||||||
| 2. | Reason for the notification | |||||||
| a) | Position/status: | SVP Commercial and General Manager, Tetris Pharma | ||||||
| b) | Initial notification/Amendment: | Initial notification | ||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a) | Name: | Arecor Therapeutics plc | ||||||
| b) | LEI: | 98450093D12I3A8DDD58 | ||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 1 pence each GB00BMWLM973 | ||||||
| b) | Nature of the transaction: | Grant of options over ordinary shares | ||||||
| c) | Price(s) and volume(s): |
| ||||||
| d) | Aggregated information: · Aggregated volume: · Price: |
213,000 N/A | ||||||
| e) | Date of the transaction: | 22 May 2024 | ||||||
| f) | Place of the transaction: | Outside of a trading venue | ||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.